Campbell, C;
Barohn, RJ;
Bertini, E;
Chabrol, B;
Comi, GP;
Darras, BT;
Finkel, RS;
... Clinical Evaluator Training Groups, .; + view all
(2020)
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
Journal of Comparative Effectiveness Research
, 9
(14)
10.2217/cer-2020-0095.
Preview |
Text
Muntoni_campbell-et-al-2020-meta-analyses-of-ataluren-randomized-controlled-trials-in-nonsense-mutation-duchenne-muscular.pdf Download (1MB) | Preview |
Abstract
Aim: Assess the totality of efficacy evidence for ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). / Materials & methods: Data from the two completed randomized controlled trials (ClinicalTrials.gov: NCT00592553; NCT01826487) of ataluren in nmDMD were combined to examine the intent-to-treat (ITT) populations and two patient subgroups (baseline 6-min walk distance [6MWD] ≥300–<400 or <400 m). Meta-analyses examined 6MWD change from baseline to week 48. / Results: Statistically significant differences in 6MWD change with ataluren versus placebo were observed across all three meta-analyses. Least-squares mean difference (95% CI): ITT (n = 342), +17.2 (0.2–34.1) m, p = 0.0473; ≥300–<400 m (n = 143), +43.9 (18.2–69.6) m, p = 0.0008; <400 m (n = 216), +27.7 (6.4–49.0) m, p = 0.0109. / Conclusion: These meta-analyses support previous evidence for ataluren in slowing disease progression versus placebo in patients with nmDMD over 48 weeks. Treatment benefit was most evident in patients with a baseline 6MWD ≥300–<400 m (the ambulatory transition phase), thereby informing future trial design.
| Type: | Article |
|---|---|
| Title: | Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2217/cer-2020-0095 |
| Publisher version: | https://doi.org/10.2217/cer-2020-0095 |
| Language: | English |
| Additional information: | Copyright © The Author 2020. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Keywords: | 6-minute walk distance, Duchenne muscular dystrophy, ataluren, efficacy, meta-analyses, nonsense mutation Duchenne muscular dystrophy, randomized controlled trials |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Neurosciences Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10109632 |
Archive Staff Only
 |
View Item |
